“西学中用,病证结合”治疗内科疾病的思想发挥
The Applicationn of the Idea of “Applying Western Learning to Chinese Medicine, Integrating Pathology with Syndrome Differentiation” in the Treatment of Internal Medicine Diseases
摘要: 本文探讨了“西学中用,病证结合”思想在中医临床中的发展与具体应用。该思想由国医大师陈绍宏教授提出,强调将西医的生理病理机制与中医的象思维、整体观和辨证论治相结合,实现中西医在理论和实践层面的深度融合。卢云教授作为陈绍宏教授的学术继承人,进一步将这一思想应用于脑出血后脑积水、急性胰腺炎恢复期及慢性阻塞性肺疾病稳定期等内科杂病的诊治中,通过病证结合、病机转化、方证相应的诊疗模式,取得了显著的临床疗效,并得到部分临床研究的支持。文章通过具体病例分析,表明“西学中用、病证结合”不仅拓展了中医诊疗思路,也为中西医结合提供了可行的路径。
Abstract: This paper explores the development and practical application of the concept “Applying Western Learning to Chinese Medicine, Integrating Pathology with Syndrome Differentiation” in clinical TCM practice. Proposed by Professor Chen Shaohong, a Master of Traditional Chinese Medicine, this approach emphasizes integrating Western medicine’s physiological and pathological mechanisms with TCM’s image-based thinking, holistic perspective, and syndrome differentiation and treatment. It aims to achieve a deep integration of Chinese and Western medicine at both theoretical and practical levels. Professor Lu Yun, as Professor Chen Shaohong’s academic successor, has further applied this concept to the diagnosis and treatment of internal medicine conditions such as post-hemorrhagic hydrocephalus, the recovery phase of acute pancreatitis, and the stable phase of chronic obstructive pulmonary disease (COPD). Through a diagnostic and therapeutic model integrating disease patterns with syndrome differentiation, transforming pathogenic mechanisms, and matching formulas to syndromes, significant clinical efficacy has been achieved, supported by some clinical research. Through specific case analyses, this article demonstrates that “Applying Western Knowledge to Chinese Medicine and Integrating Disease with Syndrome” not only broadens the diagnostic and therapeutic approach of Chinese medicine but also provides a viable pathway for the integration of Chinese and Western medicine.
文章引用:唐玥明, 夏雨航, 卢云. “西学中用,病证结合”治疗内科疾病的思想发挥[J]. 中医学, 2025, 14(10): 4203-4209. https://doi.org/10.12677/tcm.2025.1410610

参考文献

[1] 张成博, 程伟. 中国医学史[M]. 北京: 中国中医药出版社, 2016.
[2] 卢云, 焦旭. “西学中用” “病证结合”治疗危急重症[J]. 中国中医急症, 2016, 25(6): 1018-1022.
[3] 脑血管病相关性正常颅压脑积水中国专家共识[J]. 中华医学杂志, 2020(39): 3049-3057.
[4] Chang, C., Kuwana, N., Ito, S., Yokoyama, T., Kanno, H. and Yamamoto, I. (2003) Cerebral Haemodynamics in Patients with Hydrocephalus after Subarachnoid Haemorrhage Due to Ruptured Aneurysm. European Journal of Nuclear Medicine and Molecular Imaging, 30, 123-126. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, S., Luo, J., Reis, C., Manaenko, A. and Zhang, J. (2017) Hydrocephalus after Subarachnoid Hemorrhage: Pathophysiology, Diagnosis, and Treatment. BioMed Research International, 2017, Article ID: 8584753. [Google Scholar] [CrossRef] [PubMed]
[6] Yolas, C., Ozdemir, N.G., Kanat, A., Aydin, M.D., Keles, P., Kepoglu, U., et al. (2016) Uncovering a New Cause of Obstructive Hydrocephalus Following Subarachnoid Hemorrhage: Choroidal Artery Vasospasm-Related Ependymal Cell Degeneration and Aqueductal Stenosis—First Experimental Study. World Neurosurgery, 90, 484-491. [Google Scholar] [CrossRef] [PubMed]
[7] Strahle, J., Garton, H.J.L., Maher, C.O., Muraszko, K.M., Keep, R.F. and Xi, G. (2012) Mechanisms of Hydrocephalus after Neonatal and Adult Intraventricular Hemorrhage. Translational Stroke Research, 3, 25-38. [Google Scholar] [CrossRef] [PubMed]
[8] Banizs, B., Pike, M.M., Millican, C.L., Ferguson, W.B., Komlosi, P., Sheetz, J., et al. (2005) Dysfunctional Cilia Lead to Altered Ependyma and Choroid Plexus Function, and Result in the Formation of Hydrocephalus. Development, 132, 5329-5339. [Google Scholar] [CrossRef] [PubMed]
[9] 郭建文, 张晓云, 兰万成, 等. 陈绍宏教授“中风核心病机论” [J]. 天津中医药, 2006(1): 7-9.
[10] 卢云, 张晓云. 中西医结合综合方案治疗24例脑出血后脑积水的临床观察[J]. 中国中医基础医学杂志, 2014, 20(2): 271-273.
[11] 罗流, 李明非, 何刚, 等. 活血豁痰法防治急性脑出血后脑积水的多中心、前瞻性、队列研究[J]. 北京中医药大学学报, 2024, 47(5): 603-610.
[12] 中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021) [J]. 浙江实用医学, 2021, 26(6): 511-519+535.
[13] Petrov, M.S. and Yadav, D. (2018) Global Epidemiology and Holistic Prevention of Pancreatitis. Nature Reviews Gastroenterology & Hepatology, 16, 175-184. [Google Scholar] [CrossRef] [PubMed]
[14] 李慧臻, 周正华, 程红杰, 等. 急性胰腺炎中医诊疗专家共识(2023) [J]. 中华中医药杂志, 2024, 39(7): 3549-3557.
[15] Pallagi, P., Hegyi, P. and Rakonczay, Z. (2015) The Physiology and Pathophysiology of Pancreatic Ductal Secretion: The Background for Clinicians. Pancreas, 44, 1211-1233. [Google Scholar] [CrossRef] [PubMed]
[16] Rizk, A.A., Dybala, M.P., Rodriguez, K.C., Slak Rupnik, M. and Hara, M. (2023) Pancreatic Regional Blood Flow Links the Endocrine and Exocrine Diseases. Journal of Clinical Investigation, 133, e166185. [Google Scholar] [CrossRef] [PubMed]
[17] 赖文静. 益气活血法干预对急性胰腺炎恢复期的临床研究[D]: [硕士学位论文]. 成都: 成都中医药大学, 2019.
[18] Agustí, A., Celli, B.R., Criner, G.J., Halpin, D., Anzueto, A., Barnes, P., et al. (2023) Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 207, 819-837. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, C., Xu, J., Yang, L., Xu, Y., Zhang, X., Bai, C., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (The China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717. [Google Scholar] [CrossRef] [PubMed]
[20] Zhou, M., Wang, H., Zeng, X., Yin, P., Zhu, J., Chen, W., et al. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 394, 1145-1158. [Google Scholar] [CrossRef] [PubMed]
[21] GBD Chronic Respiratory Disease Collaborators (2020) Prevalence and Attributable Health Burden of Chronic Respiratory Diseases, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet. Respiratory Medicine, 8, 585-596.
[22] Kew, K.M., Mavergames, C. and Walters, J.A. (2013) Long-Acting Beta2-Agonists for Chronic Obstructive Pulmonary Disease. Cochrane Database of Systematic Reviews, 2013, CD010177. [Google Scholar] [CrossRef] [PubMed]
[23] Burge P S, Calverley P M, Jones P W, et al. (2000) Randomised, Double Blind, Placebo Controlled Study of Fluticasone Propionate in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: The ISOLDE Trial. BMJ, 320, 1297-1303. [Google Scholar] [CrossRef] [PubMed]
[24] Singh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., et al. (2016) Single Inhaler Triple Therapy versus Inhaled Corticosteroid Plus Long-Acting Β2-Agonist Therapy for Chronic Obstructive Pulmonary Disease (TRILOGY): A Double-Blind, Parallel Group, Randomised Controlled Trial. The Lancet, 388, 963-973. [Google Scholar] [CrossRef] [PubMed]
[25] Celli, B.R., Thomas, N.E., Anderson, J.A., Ferguson, G.T., Jenkins, C.R., Jones, P.W., et al. (2008) Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study. American Journal of Respiratory and Critical Care Medicine, 178, 332-338. [Google Scholar] [CrossRef] [PubMed]
[26] 慢性阻塞性肺疾病中西医结合管理专家共识写作组, 何权瀛, 冯淬灵. 慢性阻塞性肺疾病中西医结合管理专家共识(2023版) [J]. 中国全科医学, 2023, 26(35): 4359-4371.
[27] 李现东, 韩纪昌, 张祎捷, 等. 中西医结合治疗慢性阻塞性肺疾病稳定期的临床研究[J]. 中国中医基础医学杂志, 2014, 20(6): 788-790.